Incannex Healthcare Inc. Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction
Incannex Healthcare Inc. (IXHL) reported Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction of $134.63 thousand for the 12-month period ending 2022-06-30, per its 20-F filed 2023-10-31.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction · last filed 2023-10-31
| Period end | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 6 month | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 12 month |
|---|---|---|
| 2022-06-30 | $134.63K 20-F · filed 2023-10-31 | |
| 2021-12-31 | $134.63K 6-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |